• Home
  • Site Map
  • Privacy Policy
    •
     
  • Continued Acid Control
  • Provide More Options for your Patients
  • Extensive Formulary Coverage
  • Information for Pharmacists
  • Tips and Tools
  • Prescribing Information
  • Consumer Website
    •

    Print the ZEGERID Savings Coupon and help your patients start saving today!

    Terms of Use

    PLEASE READ THE FOLLOWING TERMS AND CONDITIONS CAREFULLY

    This website located at the URL www.santarus.com and any other site provided by us (collectively, this "Site") is provided to you by Santarus, Inc. ("Santarus," "we," "our" or "us"). By using this Site you are indicating your acceptance of the following terms and conditions ("Terms of Use"), which shall be legally binding on you.

    Modifications to Terms of Use and Privacy Policy

    We reserve the right, at any time, to modify, alter, update or remove portions of these Terms of Use or our Privacy Policy. Please check them from time to time as your continued use of this Site signifies your acceptance of any changed items. If we change our Terms of Use or Privacy Policy, we will change the dates listed below and post a notice to that effect on the Site's home page for at least 30 days after the change. If you have provided us with your email address, we may (but are not required to) send you an email notifying you of changes to our Privacy Policy.

    Effective Dates:
    Terms of Use - September 20, 2004
    Privacy Policy - September 20, 2004


    Privacy Policy

    We respect the privacy of information that we obtain from visitors to this Site. It is our intention to balance our legitimate business interests in collecting and using information received from and about you with your reasonable expectations of privacy.

    We collect certain personally identifiable information including your name, address, email address and phone number only when provided by you for the purpose of responding to your requests for information.

    We also collect anonymous information about the use of our Site, such as the number of visitors, the length and time of their visits, the pages they view, the web browsers they use, etc. Such anonymous data may be used by us and disclosed by us to third parties to improve our Site and to better understand your needs. Our Site does not currently use "cookies."

    We do not intentionally collect information about children under the age of thirteen. If you are under thirteen, please do not give us any personal data.

    We do not disclose any personally identifiable information about you to any third parties except under the following circumstances:

    • We will provide your information to a third party if you specifically agree that we may provide your information to a third party.
    • We may use a third-party service provider to assist with sending information by email, mail or other means. In our contracts with these providers, we have them agree that they will not retain, share, store or use your personally identifiable information for any purpose other than as stated in the contract.
    • We may need to disclose your personally identifiable information when required by law or if we have a good-faith belief that such action is necessary to comply with a court order or subpoena, to cooperate with investigations by law enforcement or regulatory authorities or to participate or cooperate with a judicial proceeding.
    • In a merger, acquisition by another company, or a sale of all or a portion of our assets, your personal information will, in most instances, be transferred to the control of a third party. We will post a notice on our Site for 30 days after a change of ownership or control of our business or assets. If you have provided us with your email address, we may (but are not required to) send you an email notifying you of such transfer.

    As a resource to you, this Site may include links to third party websites. Our privacy policy does not apply to such websites, and you should contact them directly for information regarding their privacy policies.

    We may make changes to this privacy policy from time to time. You will be notified about any changes as described above in the section entitled "Modifications to Terms of Use and Privacy Policy."

    If you have any questions regarding this Privacy Policy, would like to obtain a copy of or make changes to the personal information collected from you, or would like to have your personal information removed from our database, please send us an email at contact@santarus.com.



    Please see full prescribing information.

    You can obtain additional information about ZEGERID by writing Santarus directly. To speak to a representative by phone or to report an adverse event, call Santarus' Medical Information Department at 1.888.778.0887, option 2 (M-F, 9:00 am to 7:00 pm, EST).

    Product Description
    ZEGERID contains omeprazole, a proton pump inhibitor (PPI), and sodium bicarbonate, an antacid, which raises the gastric pH and thus protects omeprazole from acid degradation.

    Indications and Dosing for ZEGERID
    ZEGERID is indicated for heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)
    (20 mg); for the short-term treatment (4-8 weeks) of erosive esophagitis diagnosed by endoscopy
    (20 mg); for maintenance of healing of erosive esophagitis (20 mg) (controlled studies do not extend beyond 12 months); for short-term treatment (4-8 weeks) of active duodenal ulcer (20 mg); for short-term treatment (4-8 weeks) of active benign gastric ulcer (40 mg); and for reduction of risk of upper gastrointestinal bleeding in critically ill patients (only powder for oral suspension 40 mg; use beyond 14 days has not been evaluated).

    Important Safety Information about ZEGERID
    The most frequently reported adverse events with ZEGERID are headache, diarrhea, and abdominal pain. In 178 critically ill patients treated with ZEGERID Powder for oral Suspension, adverse events generally reflected the serious, underlying medical condition of the patients, and were similar for patients treated with ZEGERID Powder for oral Suspension than in those treated with the comparator (acid-controlling) drug. For more information about these and other events, please see Table 4 of the Full Prescribing Information. Symptomatic response to therapy does not preclude the presence of gastric malignancy. Atrophic gastritis has been noted occasionally in gastric corpus biopsies from patients treated long term with omeprazole.

    ZEGERID Capsules contain 304 mg of sodium per dose. ZEGERID Powder for oral Suspension contains 460 mg of sodium per dose. This should be taken into consideration for patients on a sodium-restricted diet.

    Sodium bicarbonate is contraindicated in patients with metabolic alkalosis and hypocalcemia. ZEGERID is contraindicated in patients with known hypersensitivity to any component of the formulation.

    Since both 20 mg and 40 mg ZEGERID contain the same amount of sodium bicarbonate (1100 mg in capsules,
    1680 mg in packets of powder for oral suspension), two 20 mg capsules are not equivalent to, and should not be substituted for, one 40 mg capsule, and two 20 mg packets are not equivalent to, and should not be substituted for, one 40 mg packet.

    © 2010 Santarus, Inc. All rights reserved. 1-ZEG10046

    Use of this site constitutes your acceptance of our Terms of Use and Privacy Policy.